K
Kytopen
Developing an automated cell engineering platform to accelerate discovery of bioengineered chemicals
About Kytopen
Kytopen is a pioneering biotechnology company focused on developing innovative cell engineering solutions for therapeutic applications. The company operates in the cell therapy market, specifically targeting immuno-oncology and genetic disorders. Kytopen's core product is a patent-pending, non-viral continuous cell engineering platform that enables the rapid, scalable, and gentle modification of human cells. This technology ensures the production of billions of high-quality engineered cells in minutes while maintaining their health and function, which is crucial for effective therapeutic outcomes.
Read full description
Kytopen serves a range of clients including pharmaceutical companies, research institutions, and biotechnology firms. The company’s business model revolves around the commercialization of its proprietary cell engineering platform, which can be integrated into both the discovery and manufacturing phases of cell therapy development. Revenue is generated through the sale of the platform, licensing agreements, and potentially through partnerships and collaborations with other entities in the biotech and pharmaceutical sectors.
Founded as an MIT spinout, Kytopen is led by Dr. Paulo A. Garcia and Dr. Cullen R. Buie, who co-invented the technology. The company boasts multiple publications in high-impact scientific journals, underscoring its commitment to advancing the field of cell therapy.
At a glance
- Status
- Operational
- Founded
- 2017
- Headquarters
- Cambridge, United States
- Employees
- 27
- Open positions
- None listed
- Dealroom signal
- 62.4/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Mechanical Solutions, Biotechnology, Genetics and genomics, Immune System, Synthetic Biology, Crispr, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- SaaS
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Apr 2026 | — | — | Telegraph Hill Partners | ↗ |
| GRANT✓Other financing | Aug 2024 | $1.6M | — | National Institutes of Health | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Kytopen is 2.4K monthly website visits, up 60% over the last three months. Kytopen's team declined 12.9% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed5 investors entered at this stage
The Engine
MassVentures
Massachusetts Clean Energy Center
Horizons Ventures
National Institutes of Health
Series A6 investors entered at this stage
Northpond Ventures
Michael Chambers
John Ballantyne
Horizon Ventures
Alexandria Venture Investments
Telegraph Hill Partners
Other known investors5 additional known investors
Massachusetts Institute of Technology- BGBantam Group
Engine Ventures
Small Business Innovation Research
TBD Angels
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Kytopen on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Kytopen’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.